CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea
· Delayed Price · Currency is KRW 10,220
+140 (1.39%)
Last updated: Apr 28, 2025
CJ Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 3,467 | 5,575 | 4,075 | 4,363 | 5,312 | Upgrade
|
| Other Revenue | - | -0 | - | - | - | Upgrade
|
| Revenue | 3,467 | 5,575 | 4,075 | 4,363 | 5,312 | Upgrade
|
| Revenue Growth (YoY) | -37.82% | 36.82% | -6.61% | -17.86% | 11.04% | Upgrade
|
| Cost of Revenue | 3,182 | 3,802 | 2,763 | 2,721 | 3,072 | Upgrade
|
| Gross Profit | 284.83 | 1,773 | 1,311 | 1,642 | 2,240 | Upgrade
|
| Selling, General & Admin | 9,668 | 9,371 | 12,970 | 5,934 | 5,375 | Upgrade
|
| Research & Development | 23,167 | 22,823 | 19,186 | 4,852 | 4,984 | Upgrade
|
| Other Operating Expenses | 221.72 | 203.41 | 111.59 | 77.13 | 17.09 | Upgrade
|
| Operating Expenses | 34,526 | 33,829 | 34,545 | 11,750 | 10,753 | Upgrade
|
| Operating Income | -34,241 | -32,057 | -33,233 | -10,108 | -8,513 | Upgrade
|
| Interest Expense | -587.41 | -922.05 | -2,763 | -4,968 | -1,622 | Upgrade
|
| Interest & Investment Income | 1,913 | 1,367 | 1,331 | 410.15 | 337.88 | Upgrade
|
| Earnings From Equity Investments | - | 75.66 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -68.27 | -39.39 | 12.64 | 2.91 | 0.69 | Upgrade
|
| Other Non Operating Income (Expenses) | 134.84 | 19.86 | 129.82 | -2,485 | 1,124 | Upgrade
|
| EBT Excluding Unusual Items | -32,849 | -31,555 | -34,523 | -17,148 | -8,673 | Upgrade
|
| Gain (Loss) on Sale of Assets | 10.89 | 8,642 | -390.7 | 10.43 | -89.96 | Upgrade
|
| Asset Writedown | - | - | - | -170.67 | - | Upgrade
|
| Other Unusual Items | - | - | - | -1,964 | - | Upgrade
|
| Pretax Income | -32,838 | -22,913 | -34,913 | -19,272 | -8,763 | Upgrade
|
| Net Income | -32,838 | -22,913 | -34,913 | -19,272 | -8,763 | Upgrade
|
| Net Income to Common | -32,838 | -22,913 | -34,913 | -19,272 | -8,763 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 7 | 6 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 7 | 6 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 30.93% | 20.52% | 38.23% | 10.14% | 16.93% | Upgrade
|
| EPS (Basic) | -3540.64 | -3234.63 | -5940.02 | -4532.31 | -2269.60 | Upgrade
|
| EPS (Diluted) | -3541.00 | -3235.00 | -5940.02 | -4533.00 | -2270.00 | Upgrade
|
| Free Cash Flow | -28,138 | -29,823 | -25,108 | -9,390 | -19,997 | Upgrade
|
| Free Cash Flow Per Share | -3033.88 | -4210.07 | -4271.74 | -2208.24 | -5179.37 | Upgrade
|
| Gross Margin | 8.22% | 31.80% | 32.19% | 37.62% | 42.17% | Upgrade
|
| Operating Margin | -987.76% | -575.00% | -815.61% | -231.68% | -160.28% | Upgrade
|
| Profit Margin | -947.28% | -410.99% | -856.84% | -441.72% | -164.97% | Upgrade
|
| Free Cash Flow Margin | -811.70% | -534.93% | -616.19% | -215.22% | -376.48% | Upgrade
|
| EBITDA | -29,920 | -26,911 | -29,333 | -8,546 | -7,462 | Upgrade
|
| EBITDA Margin | - | - | - | -195.88% | -140.49% | Upgrade
|
| D&A For EBITDA | 4,321 | 5,146 | 3,900 | 1,562 | 1,051 | Upgrade
|
| EBIT | -34,241 | -32,057 | -33,233 | -10,108 | -8,513 | Upgrade
|
| EBIT Margin | - | - | - | -231.67% | -160.28% | Upgrade
|
| Advertising Expenses | 123.79 | 160.85 | 131.39 | 58.02 | 979.43 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.